Patents by Inventor Jurgen Hemberger
Jurgen Hemberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10564129Abstract: The present invention relates to a method of testing the mechanical integrity of a cartridge (10) containing a medicament and being arranged inside a drug delivery device (20). The invention also relates to a testing arrangement and to a respective drug delivery device, wherein the method comprises the steps of: acoustically stimulating the cartridge (10), measuring of the cartridge's (10) acoustic response (60) to the acoustic stimulation (32), comparing the acoustic response (60) with a standard response (62) of an intact cartridge (10), and determining the mechanical integrity of the cartridge (10) on the basis of the comparison.Type: GrantFiled: August 4, 2015Date of Patent: February 18, 2020Assignee: Sanofi-Aventis Deutschland GMBHInventors: Hanno Juhnke, Jan-Peter Spengler, Jasmin Groeschke, Anne Boker, Michael Fischer, Matthias Scharf, Michael Schrack, Olaf Zeckai, Jurgen Hemberger
-
Publication number: 20180017531Abstract: The present invention relates to a method of testing the mechanical integrity of a cartridge (10) containing a medicament and being arranged inside a drug delivery device (20). The invention also relates to a testing arrangement and to a respective drug delivery device, wherein the method comprises the steps of: acoustically stimulating the cartridge (10), measuring of the cartridge's (10) acoustic response (60) to the acoustic stimulation (32), comparing the acoustic response (60) with a standard response (62) of an intact cartridge (10), and determining the mechanical integrity of the cartridge (10) on the basis of the comparison.Type: ApplicationFiled: August 4, 2015Publication date: January 18, 2018Inventors: Hanno Juhnke, Jan-Peter Spengler, Jasmin Groeschke, Anne Boker, Michael Fischer, Matthias Scharf, Michael Schrack, Olaf Zeckai, Jurgen Hemberger
-
Patent number: 8916518Abstract: The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: GrantFiled: May 28, 2009Date of Patent: December 23, 2014Assignee: Fresenius Kabi Deutschland GmbHInventors: Jurgen Hemberger, Michele Orlando, Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Katharina Lutterbeck, Cornelius Jungheinrich, Roland Scharpf
-
Patent number: 8466277Abstract: The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the low-molecular weight substance which reacts with this aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: GrantFiled: February 28, 2003Date of Patent: June 18, 2013Assignee: Fresenius Kabi Deutschland GmbHInventors: Michele Orlando, Jurgen Hemberger, Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Katharina Lutterbeck, Cornelius Jungheinrich, Roland Scharpf
-
Publication number: 20120259107Abstract: The invention relates to a method for coupling low-molecular substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the low-molecular substance which reacts with this aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: ApplicationFiled: June 12, 2012Publication date: October 11, 2012Inventors: Michele Orlando, Jurgen Hemberger, Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Katharina Lutterbeck, Cornelius Jungheinrich, Roland Scharpf
-
Patent number: 7816516Abstract: The invention relates to compounds, comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate, whereby HAS and an active agent are reacted in a reaction medium, characterised in that the reaction medium is water or a mixture of water and an organic solvent, comprising at least 10 wt. % water.Type: GrantFiled: March 15, 2002Date of Patent: October 19, 2010Assignee: Fresenius Kabi Deutschland GmbHInventors: Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Cornelius Jungheinrich, Roland Scharpf, Katharina Lutterbeck, Jurgen Hemberger, Michele Orlando
-
Publication number: 20090233847Abstract: The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: ApplicationFiled: May 28, 2009Publication date: September 17, 2009Inventors: Jurgen Hemberger, Michele Orlando, Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Katharina Lutterbeck, Cornelius Jungheinrich, Roland Scharpf
-
Patent number: 7541328Abstract: The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: GrantFiled: February 28, 2003Date of Patent: June 2, 2009Assignee: Fresenius Kabi Deutschland GmbHInventors: Jurgen Hemberger, Michele Orlando, Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Katharina Lutterbeck, Cornelius Jungheinrich, Roland Scharpf
-
Patent number: 7538092Abstract: The present invention relates to pharmaceutically active oligosaccharide conjugates having the formula: (X—Ym)n—S, wherein component X is a pharmaceutically active compound, Y is a bifunctional linker, and S is an oligosaccharide consisting of 1 to 20 saccharide units, n is equal or less than the number of the saccharide units in the oligosaccharide S, and m is, independent of n, 0 or 1. In addition, the present invention is directed to a process of preparing compounds of the present invention, comprising the step of coupling components X and S directly or indirectly by means of a bifunctional linker group. Furthermore, the present invention relates to the use of said pharmaceutically active oligosaccharide conjugates as a medicament as well as to pharmaceutical compositions, freeze-dried pharmaceutical compositions, and a kit, all of which comprise at least one of said pharmaceutically active oligosaccharide conjugates.Type: GrantFiled: October 8, 2003Date of Patent: May 26, 2009Assignee: Fresenius Kabi Deutschland GmbHInventors: Michele Orlando, Jurgen Hemberger, Jeanne Delbos-Krampe
-
Publication number: 20060217293Abstract: The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the low-molecular weight substance which reacts with this aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: ApplicationFiled: February 28, 2003Publication date: September 28, 2006Inventors: Michele Orlando, Jurgen Hemberger
-
Patent number: 7090986Abstract: A naturally occurring protein isolated from the saliva of the medicinal leech Hirudo medicinalis is described which strongly binds to collagen thus acting as an inhibitor of natural platelet adhesion to collagen. The protein has a molecular weight of about 12,000, an acidic isoelectric point and contains six cysteins. The protein was sequenced and the gene was cloned from a H. medicinalis cDNA-library. Procedures for producing such polypeptide by recombinant techniques are disclosed. The recombinant and the natural occurring proteins are potent inhibitors of collagen-dependent platelet adhesion and therefore useful for the therapeutic treatment of various conditions related to heart disease and diseases of the circulation system. Furthermore, the protein is useful for coating natural or artificial collagen surfaces in order to render them nonadhesive for cells and prevent the activation of cells.Type: GrantFiled: June 16, 2005Date of Patent: August 15, 2006Assignee: Merck Patent GmbHInventors: Wolfgang Strittmatter, Detlef Güssow, Uwe Hofmann, Jürgen Hemberger, Zisi Fotev, Bernhard Scheuble
-
Publication number: 20060100163Abstract: The present invention relates to pharmaceutically active oligosaccharide conjugates having the formula: (X—Ym)n—S, wherein component X is a pharmaceutically active compound, Y is a bifunctional linker, and S is an oligosaccharide consisting of 1 to 20 saccharide units, n is equal or less than the number of the saccharide units in the oligosaccharide S, and m is, independent of n, 0 or 1. In addition, the present invention is directed to a process of preparing compounds of the present invention, comprising the step of coupling compounents X and S directly or indirectly by means of a bifunctional linnker group. Furthermore, the present invention relates ot the use of said pharmaceutically active oligosaccharide conjugates as a medicament as well as to pharmaceutical compositions, freeze-dried pharmaceutical compositions, and a kit, all of which comprise at least one of said pharmaceutically active oligosaccharide conjugates.Type: ApplicationFiled: October 8, 2003Publication date: May 11, 2006Inventors: Michele Orlando, Jurgen Hemberger, Jeanne Delbos-Krampe
-
Publication number: 20060094079Abstract: A naturally occurring protein isolated from the saliva of the medicinal leech Hirudo medicinalis is described which strongly binds to collagen thus acting as an inhibitor of natural platelet adhesion to collagen. The protein has a molecular weight of about 12,000, an acidic isoelectric point and contains six cysteins. The protein was sequenced and the gene was cloned from a H. medicinalis cDNA-library. Procedures for producing such polypeptide by recombinant techniques are disclosed. The recombinant and the natural occurring proteins are potent inhibitors of collagen-dependent platelet adhesion and therefore useful for the therapeutic treatment of various conditions related to heart disease and diseases of the circulation system. Furthermore, the protein is useful for coating natural or artificial collagen surfaces in order to render them nonadhesive for cells and prevent the activation of cells.Type: ApplicationFiled: June 16, 2005Publication date: May 4, 2006Inventors: Wolfgang Strittmatter, Detlef Gussow, Uwe Hofmann, Jurgen Hemberger, Zisi Fotev, Bernhard Scheuble
-
Publication number: 20050267169Abstract: The present invention relates to propofol derivatives comprising a cyclic or linear amino acid, or a poly- or (oligo)saccharide moiety, a process for preparing said derivatives, a method for anesthetizing a mammal as well as a method for treating convulsions, migraine or related diseases, or for the inhibition of free radicals in a mammal to which said compounds are administered. Furthermore, the present invention relates to said compounds for use as a medicament and the use of said compounds for the preparation of a medicament for anesthetizing a mammal or for treating convulsions, migraine or related diseases, or for inhibition of free radicals in a mammal.Type: ApplicationFiled: April 7, 2005Publication date: December 1, 2005Inventors: Michele Orlando, Jurgen Hemberger, Giuseppe Trapani, Gaetano Liso, Cosimo Altomare, Andrea Latrofa, Giovanni Biggio, Mariangela Serra, Enrico Sanna, Valentino Laquintana
-
Patent number: 6962801Abstract: A naturally occurring protein isolated from the saliva of the medicinal leech Hirudo medicinalis is described which strongly binds to collagen thus acting as an inhibitor of natural platelet adhesion to collagen. The protein has a molecular weight of about 12,000, an acidic isoelectric point and contains six cysteins. The protein was sequenced and the gene was cloned from a H. medicinalis cDNA-library. Procedures for producing such polypeptide by recombinant techniques are disclosed. The recombinant and the natural occurring proteins are potent inhibitors of collagen-dependent platelet adhesion and therefore useful for the therapeutic treatment of various conditions related to hard disease and diseases of the circulation system. Furthermore the protein is useful for coating natural or artificial collagen surfaces in order to render them nonadhesive for cells and prevent the activation of cells.Type: GrantFiled: May 17, 2004Date of Patent: November 8, 2005Assignee: Merck Patent GmbHInventors: Wolfgang Strittmatter, Detlef Güssow, Uwe Hofmann, Jürgen Hemberger, Zisi Fotev, Bernhard Scheuble
-
Publication number: 20050181985Abstract: The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.Type: ApplicationFiled: February 28, 2003Publication date: August 18, 2005Inventors: Jurgen Hemberger, Michele Orlando
-
Publication number: 20050065084Abstract: A naturally occurring protein isolated from the saliva of the medicinal leech Hirudo medicinalis is described which strongly binds to collagen thus acting as an inhibitor of natural platelet adhesion to collagen. The protein has a molecular weight of about 12 000, an acidic isoelectric point and contains six cysteins. The protein was sequenced and the gene was cloned from a H. medicinalis cDNA-library. Procedures for producing such polypeptide by recombinant techniques are disclosed. The recombinant and the natural occurring proteins are potent inhibitors of collagen-dependent platelet adhesion and therefore useful for the therapeutic treatment of various conditions related to hard disease and diseases of the circulation system. Furthermore the protein is useful for coating natural or artificial collagen surfaces in order to render them nonadhesive for cells and prevent the activation of cells.Type: ApplicationFiled: May 17, 2004Publication date: March 24, 2005Inventors: Wolfgan Strittmatter, Detlef Gussow, Uwe Hofmann, Jurgen Hemberger, Zisi Fotev, Bernhard Scheuble
-
Patent number: 6774107Abstract: A naturally occurring protein isolated from the saliva of the medicinal leech Hirudo medicinalis is described which strongly binds to collagen thus acting as an inhibitor of natural platelet adhesion to collagen. The protein has a molecular weight of about 12,000, an acidic isoelectric point and contains six cysteins. The protein was sequenced and the gene was cloned from a H. medicinalis cDNA-library. Procedures for producing such polypeptide by recombinant techniques are disclosed. The recombinant and the natural occurring proteins are potent inhibitors of collagen-dependent platelet adhesion and therefore useful for the therapeutic treatment of various conditions related to heart disease and diseases of the circulation system. Furthermore, the protein is useful for coating natural or artificial collagen surfaces in order to render them nonadhesive for cells and prevent the activation of cells.Type: GrantFiled: September 17, 2001Date of Patent: August 10, 2004Assignee: Merck Patent GmbHInventors: Wolfgang Strittmatter, Detlef Güssow, Uwe Hofmann, Jürgen Hemberger, Zisi Fotev, Bernhard Scheuble
-
Patent number: 5710131Abstract: A protein isolated from crude extracts of Hirudo medicinalis is disclosed, which strongly inhibits the binding to collagen of platelets and their subsequent activation, which leads to platelet aggregation and thrombus formation. Additionally the protein prevents binding of von Willebrand factor to collagen. Described is a method for isolation and purification of the protein as well as its use for blocking collagen-stimulated platelet aggregation. The new protein (Brandinin) has a molweight of approximately 15 kD, binds to collagen but has no collagen-cleaving activity. The protein is useful in the prophylaxis, prevention and treatment of thrombotic diseaeses and for coating of blood-contacting materials, rendering them thromboresistant.Type: GrantFiled: February 28, 1995Date of Patent: January 20, 1998Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Jurgen Hemberger, Guido Melzer
-
Patent number: 5670049Abstract: The invention relates to sorbents for for ?sic! affinity chromatography which are based on hydroxyl-containing base supports on whose surfaces polymers are covalently bonded, characterized in thata) the base support contains aliphatic hydroxyl groups,b) the covalently bonded polymers are bound to the base support by a terminal monomer unit,c) the polymers contain monomer units of the formula IId) the monomer units are linked linearly, ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 independently of one another are H or CH.sub.3,R.sup.4 is H, C.sub.1 -C.sub.5 -alkyl or C.sub.6 -C.sub.12 -aryl,n is an integer between 1 and 5 andone of the radicals X is OH and the other radical X is a nucleoside-containing radical,and to their preparation and use, especially for affinity chromatography.Type: GrantFiled: April 1, 1996Date of Patent: September 23, 1997Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Egbert Muller, Jurgen Hemberger, Michael Morr